Applied Biosystems Expands its Line of siRNAs for Biomedical Research
Complete the form below to unlock access to ALL audio articles.
Applied Biosystems has announced the availability of a new line of synthetic short interfering ribonucleic acids (siRNA).
The Company says that the Silencer® Select siRNAs expand its portfolio of siRNA products and were developed to deliver the most consistent gene silencing and gene function data available to biomedical researchers performing ribonucleic acid interference (RNAi) experiments.
Silencer Select siRNAs help biomedical researchers by providing a set of pre-designed siRNAs that have been developed using a new proprietary siRNA design algorithm to silence specific genes and chemical modifications to enhance the specificity of the silencing effect. This combination of enhanced design and chemical modification results in consistent gene silencing at lower siRNA concentrations and with fewer off-target effects. Off-target effects are results that inadvertently affect expression of genes other than the intended target.
The siRNA design process is a critical step in successful gene silencing. Utilizing computer algorithms to design siRNAs has been shown to produce more reliable siRNAs than the time intensive process of manually selecting siRNAs for target gene sequences.
Applied Biosystems’ proprietary siRNA design algorithm was developed by Applied Biosystems’ Ambion business by analyzing performance data from thousands of siRNA experiments to better understand the link between a siRNA’s sequence, target location, thermodynamic properties and its silencing efficiency. This new siRNA design process yields effective siRNAs and ensures that target silencing is consistently achieved, as measured by TaqMan® Gene Expression Assays.
To validate the performance of the Silencer Select siRNAs, Applied Biosystems tested hundreds of Silencer Select siRNAs for silencing efficiency using cell-based assays. As part of this study, Applied Biosystems compared the performance of 94 different siRNAs from three different vendors targeting seven different, well characterized genes.
The results showed that pre-designed Silencer Select siRNAs effectively elicited the expected, silenced phenotypes 92 per cent of the time whereas the siRNAs from other vendors elicited the expected result in only 57-72 per cent of the siRNAs tested1. This improved efficacy is expected to give researchers greater confidence in the Silencer Select siRNAs and generate reliable data that can be used to understand gene function.
“RNAi research technologies are greatly accelerating the functional characterization of disease-relevant genes, thereby providing a critical drug discovery and development tool for a growing number of biomedical and pharmaceutical laboratories,” said Peter Dansky, president for Applied Biosystems’ molecular and cell biology consumables division.
“The Silencer Select siRNAs and our complete line of products for the RNAi workflow provide best-in-class solutions that are enabling researchers to advance the performance of gene silencing experiments and generate high-quality gene function and target validation data,” continued Dansky.
